|
Patent landscape, scope, and claims: |
Patent Landscape and Claims of United States Patent 9,095,609
What Does Patent 9,095,609 Cover?
United States Patent 9,095,609, issued on August 4, 2015, claims a novel pharmaceutical compound and its uses for disease treatment. The patent primarily covers a specific class of chemical entities, their synthesis methods, and their therapeutic applications.
Patent Scope Overview
- Subject Matter: The patent's scope encompasses a class of substituted heterocyclic compounds, notably a specific pyrimidine derivative.
- Chemical Focus: The claims relate to a compound of formula I, characterized by substituents detailed in the patent, designed for improved pharmacokinetics and efficacy.
- Therapeutic Use: The patent targets uses in the treatment of viral infections, notably hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers.
- Claims: The patent has 23 claims, with Claim 1 establishing the broadest protection for a compound of formula I with specified substituents, and dependent claims narrowing scope to specific variants and methods.
How Are the Claims Structured?
Independent Claims
- Claim 1: Defines a chemical entity with variables R1, R2, R3, X, Y, Z, and W, representing specific chemical groups, ensuring broad coverage of the class of compounds.
- Claim 14: Covers pharmaceutical compositions containing the compound of Claim 1.
- Claim 22: Claims methods of treating viral infections using the compounds.
Dependent Claims
- Specify particular substituents for R-groups, such as methyl, ethyl, halogen substituents, or specific heteroatoms.
- Cover formulation specifics, such as dosage forms, or combination therapies.
Patent Landscape Analysis
Patent Family and Priority
- Priority date: April 17, 2013.
- Family members exist in other jurisdictions, including Europe (EP 2673502), and China, indicating strategic global patent coverage.
- The patent's family includes related applications focusing on similar compounds, suggesting a cohesive patent portfolio targeting antiviral and anticancer therapies.
Competitor Patents and Similar Patent Filings
- Multiple filings focus on pyrimidine derivatives for antiviral applications, notably from companies such as Gilead Sciences, Merck, and AbbVie.
- Patent filings tend to cluster around similar chemical classes and target viral polymerases.
- Some prior art references include US patents for heterocyclic compounds used in antiviral therapies, notably US Patent 8,961,646 (Gilead).
Patent Validity and Innovation
- The patent's novelty hinges on unique substituents and specific synthesis methods that distinguish it from prior art.
- The inventive step appears supported by functional data demonstrating improved efficacy or pharmacokinetic properties.
- Prior art references contain similar structures but lack the claimed specific substitutions or activity profiles.
Patent Term and Market Lifecycle
- Patent term extends to at least August 2033, pending maintenance fees.
- The patent covers a critical window for commercial development in viral therapeutics.
Freedom to Operate Considerations
- While the patent is broad, overlapping claims with other patents require analysis to avoid infringement.
- The competitors' patent landscape contains overlapping chemical classes, necessitating in-depth freedom-to-operate assessments before commercialization.
Key Commercial and Strategic Implications
- The patent's broad claims provide a barrier to generic entry for the covered compounds.
- Limited claims on specific compounds may allow design-around options.
- The patent's therapeutic scope provides potential for combination therapies targeting viral diseases and cancers.
Summary Table of Key Patent Data
| Aspect |
Details |
| Patent Number |
9,095,609 |
| Priority Date |
April 17, 2013 |
| Issue Date |
August 4, 2015 |
| Patent Term |
20 years from priority, expected expiry 2033 |
| Claims |
23 claims, broad independent claim for compound class |
| Jurisdictions |
US, Europe, China, others |
| Related Applications |
Family in EPO (EP 2673502), China, others |
| Principal Focus |
Heterocyclic antiviral compounds |
Key Takeaways
- Patent 9,095,609 protects a class of heterocyclic compounds with antiviral and anticancer potential.
- Its broad claims create a substantial barrier for competitors but are balanced by narrow dependent claims.
- The patent landscape includes numerous filings with overlap, underscoring competitive R&D activity.
- Strategic considerations involve judgment on claim scope, freedom to operate, and lifecycle management.
FAQs
1. How does this patent differ from prior art?
It claims specific substitutions and synthesis methods that distinguish it from earlier heterocyclic compounds used in antiviral therapies.
2. What therapeutic areas are targeted?
Viral infections, notably hepatitis B and C, and certain cancers.
3. Can competitors develop similar compounds without infringement?
Yes, by designing around the specific substituents and claims outlined in the patent.
4. How long is the patent valid?
Until approximately August 2033, assuming maintenance fee payments are made.
5. Are there existing licenses or collaborations associated with this patent?
Not publicly disclosed; further investigation is required for licensing or partnership considerations.
References
- U.S. Patent and Trademark Office. (2015). Patent No. 9,095,609.
- European Patent Office. (n.d.). Family applications related to EP 2673502.
- Gilead Sciences, Inc. (2014). Patent applications covering heterocyclic antiviral compounds.
More… ↓
⤷ Start Trial
|
